The question about Yupelri and steroids appears to be a misunderstanding or a conflation with other medications. Yupelri (specifically, a dry powder inhaler formulation of Yupelri was approved by the FDA in 2022) is not a steroid. It is a bronchodilator used to manage chronic obstructive pulmonary disease (COPD) [1].
How does Yupelri work for COPD?
Yupelri contains revefenacin, which is a long-acting muscarinic antagonist (LAMA). LAMAs work by blocking the action of acetylcholine, a substance in the lungs that causes smooth muscles to contract and narrow the airways. By blocking acetylcholine, revefenacin relaxes these muscles, opening up the airways and making it easier to breathe [1].
What is COPD?
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes breathing difficult. It encompasses conditions such as emphysema and chronic bronchitis [1].
When does Yupelri's patent expire?
Information on the specific patent expiry dates for Yupelri is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods, which could be consulted for this information [2].
Are there other treatments for COPD?
Yes, other treatments for COPD include other types of bronchodilators (like short-acting and long-acting beta-agonists), inhaled corticosteroids, combination inhalers, pulmonary rehabilitation, and in severe cases, oxygen therapy or surgery [1]. It is important to note that inhaled corticosteroids are a distinct class of medication from LAMAs like Yupelri, though they are sometimes used in combination for COPD management.
What are the side effects of Yupelri?
Common side effects associated with Yupelri include upper respiratory tract infection, cough, and pain in the mouth and throat [1].
---
Sources:
[1] https://www.yupelri.com/
[2] https://drugpatentwatch.com/